Inbrija is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat “off” episodes in people with Parkinson’s disease (PD) who are taking oral levodopa/carbidopa.
Inbrija is an inhaled formulation of levodopa. Levodopa is the precursor molecule to the neurotransmitter dopamine. Lowered levels of dopamine are the cause of motor symptoms in people with Parkinson’s. Levodopa is believed to treat Parkinsonian motor symptoms by increasing the concentration of dopamine in the brain.
How do I take it?
Inbrija can be taken a maximum of five times a day.
Inbrija comes in the form of powder capsules that are orally inhaled using a special inhaler.
The FDA-approved label for Inbrija lists common side effects including cough, nausea, upper respiratory tract infection, and discolored saliva.
Rare but serious side effects listed for Inbrija include falling asleep during daily activities, impulse control, and psychotic symptoms such as hallucinations.
For more details about this treatment, visit:
Inbrija – Acorda Therapeutics